Protein Phosphatase 2A - Pipeline Review, H2 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 16, 2020--
The “Protein Phosphatase 2A (PP2A or EC 184.108.40.206) - Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Protein Phosphatase 2A (PP2A or EC 220.127.116.11) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Protein Phosphatase 2A (PP2A or EC 18.104.22.168) - Pipeline Review, H2 2019, outlays comprehensive information on the Protein Phosphatase 2A (PP2A or EC 22.214.171.124) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Protein Phosphatase 2A (PP2A or EC 126.96.36.199) - Protein Phosphatase 2A (PP2A) is an enzyme encoded by the PPP2CA gene. PP2A plays important roles in regulation of cell cycle, signal transduction, cell differentiation, and transformation. Its activity is related to several diseases, including neurodegenerative diseases and cancer. The molecules developed by companies in Phase II and Preclinical stages are 2 and 3 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Gastrointestinal, Metabolic Disorders, Ophthalmology and Respiratory which include indications Hepatocellular Carcinoma, Lung Cancer, Ovarian Cancer, Allergic Conjunctivitis, Alzheimer’s Disease, Asthma, Breast Cancer, Carcinoid Tumor, Chronic Lymphocytic Leukemia (CLL), Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Crohn’s Disease (Regional Enteritis), Depression, Duodenal Cancer, Idiopathic Pulmonary Fibrosis, Insulin Resistance, Ischemic Stroke, Melanoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelodysplastic Syndrome, Myocardial Ischemia, Non-Small Cell Lung Cancer, Obesity, Pancreatic Cancer, Pheochromocytoma, Post-Traumatic Stress Disorder (PTSD), Recurrent Glioblastoma Multiforme (GBM), Sarcomas, Septic Shock, Small-Cell Lung Cancer, Soft Tissue Sarcoma, Solid Tumor, Testicular Cancer, Thymoma (Thymic Epithelial Tumor), Triple-Negative Breast Cancer (TNBC), Type 2 Diabetes, Ulcerative Colitis and Uveitis.
Furthermore, this report also reviews key players involved in Protein Phosphatase 2A (PP2A or EC 188.8.131.52) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Reasons to buy
Key Topics Covered:
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/aw7xqo
View source version on businesswire.com:https://www.businesswire.com/news/home/20200116005449/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: EDUCATION HEALTH GENETICS PHARMACEUTICAL UNIVERSITY BIOTECHNOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2020.
PUB: 01/16/2020 08:13 AM/DISC: 01/16/2020 08:13 AM